A bibliometric analysis of the 100 most-influential papers in the field of anti-diabetic drugs

Figures & data

Figure 1. Total citations of articles in the list each year.

Figure 2. Number of publications in each 5-year interval.

Figure 3. Countries with ten or more articles in the top 100 list.

Table 1. Authors with ≥5 articles in the top 100 list.

Study	Publications (n)
Rosenstock, J	9
Zinman, B	9
Woo, V	8
Lachin, JM	7
Buse, JB	6
Gerstein, HC	6
Hanefeld, M	6
Holman, RR	6
Leiter, LA	6
Riddle, MC	6
Burgess, L	5
Cartasegna, L	5
Conway, J	5
Dumas, R	5
Holst, JJ	5
Hramiak, I	5
Lochnan, H	5
Petit, C	5

Table 2. Journals with >1 article in the list.

Name of journal	Articles (n)	Impact factor	Eigenfactor	CiteScore	SNIP	SJR
New England Journal of Medicine	44	176.079	0.682	134.4	17.194	26.015
Lancet	18	202.731	0.407	133.2	25.787	14.607
Diabetes Care	7	17.152	0.117	27.8	4.781	6.008
Diabetes	5	9.337	0.087	12.3	1.654	2.635
Diabetologia	3	10.46	0.053	17.6	2.486	3.349
British Medical Journal	2	93.333	0.162	15.3	8.667	2.867
Circulation	2	39.918	0.269	42.1	6.144	7.800
Journal Of Clinical Investigation	2	19.456	0.185	23.7	2.423	5.117
Nature	2	69.504	1.443	83.4	11.591	20.957

Table 3. Institution affiliated ≥6 articles in the list.

Name of institute	Articles (n)
University of Toronto	16
Harvard Medical School	10
Saint Michael's Hospital University of Toronto	10
University of Oxford Medical Sciences Division	8
Novo Nordisk A/S	8
The George Washington University	7
Oregon Health & Science University	7
UNC School of Medicine	7
Københavns Universitet	7
University of Glasgow	6
Mount Sinai Hospital of University of Toronto	6
Imperial College London	6
Brigham and Women's Hospital	6
University of Texas Health Science Center at San Antonio	6
UT Southwestern Medical Center	6

Table 4. Top anti-diabetic drug classes.

Drug class	Number of articles
Insulin	24
>1 drug class	23
Incretin mimetics (GLP-1 agonists/analog)	17
SGLT2i	9
Thiazolidinediones (TZDs)	9
Biguanides (including metformin)	8
DPP4i	4
Sulphonylurea	3
Alpha-glucosidase inhibitors (AGIs)	2
IL-1 receptor antagonist	1

Table 5. Institutes that funded ≥6 articles.

Funding	Number of articles
National Institute of Diabetes and Digestive and Kidney Diseases	15
National Institutes of Health	7
Novo Nordisk	7
AstraZeneca	6
National Center for Advancing Translational Sciences	6
National Center for Research Resources	6
National Eye Institute	6

Table 6. Types of funding received by & number of conflict of interests (COI) reported by articles.

Funding (out of top 100)	Articles (n)
Total
Private	76
Public	49
Non-profit	31
None	4
Only funded by one type
Only privately funded	37
Only publicly funded	9
Only non-profit funded	4
Conflict of interest (COI)	Articles (n)
Number of articles with at least one COI	66/100
Mean number of authors with COI in an article	5.23
Median number of authors with COI in an article	2
Minimum COI of an article	0
Maximum COI of an article	39

Figure 4. Gender distribution based on first and senior authorship within the top 100 list.